We are live on ! Find out more
IBT

International Biotechnology Trust Portfolio holdings

AUM $297M
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
-0.44%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$256M
AUM Growth
-$27.3M
Cap. Flow
-$13M
Cap. Flow %
-5.06%
Top 10 Hldgs %
49.1%
Holding
75
New
10
Increased
14
Reduced
12
Closed
12

Top Buys

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$9.88M
2
SHPG
Shire pic
SHPG
+$9.33M
3
ARRY
Array Biopharma Inc
ARRY
+$5.99M
4
IONS icon
Ionis Pharmaceuticals
IONS
+$3.81M
5
SAGE
Sage Therapeutics
SAGE
+$3.23M

Top Sells

Rank Stock Value
1
NKTR icon
Nektar Therapeutics
NKTR
+$12.6M
2
ENTL
Entellus Medical, Inc. Common Stock
ENTL
+$8.32M
3
ACAD icon
Acadia Pharmaceuticals
ACAD
+$8.06M
4
AMGN icon
Amgen
AMGN
+$6.28M
5
BIIB icon
Biogen
BIIB
+$6.02M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SGMO
51
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$1M 0.39%
53,000
-132,000
-71% -$2.82M
HZNP
52
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$979K 0.38%
69,000
– –
ACAD icon
53
Acadia Pharmaceuticals
ACAD
$5.12B
$961K 0.37%
42,773
-291,000
-87% -$8.06M
SUPN icon
54
Supernus Pharmaceuticals
SUPN
$2.57B
$959K 0.37%
20,953
– –
ANAB icon
55
AnaptysBio
ANAB
$1.7B
$885K 0.35%
8,500
-8,500
-50% -$958K
FOLD
56
DELISTED
Amicus Therapeutics
FOLD
$881K 0.34%
58,600
– –
AERI
57
DELISTED
Aerie Pharmaceuticals
AERI
$802K 0.31%
14,779
– –
ONCE
58
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$799K 0.31%
12,000
– –
PTLA
59
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$784K 0.31%
24,000
– –
ESPR
60
DELISTED
Esperion Therapeutics
ESPR
$723K 0.28%
+10,000
New +$734K
RDUS
61
DELISTED
Radius Health, Inc.
RDUS
$675K 0.26%
18,799
– –
FOMX
62
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$324K 0.13%
63,202
-319,636
-83% -$1.92M
VKTX icon
63
Viking Therapeutics
VKTX
$3.95B
$305K 0.12%
70,000
– –
AMGN icon
64
Amgen
AMGN
$236B
– –
-36,104
Closed -$6.28M
MDGL icon
65
Madrigal Pharmaceuticals
MDGL
$12.6B
– –
-25,000
Closed -$2.29M
NKTR icon
66
Nektar Therapeutics
NKTR
$2.55B
– –
-14,067
Closed -$12.6M
OMER icon
67
Omeros
OMER
$1.39B
– –
-34,000
Closed -$660K
PRTA icon
68
Prothena Corp
PRTA
$467M
– –
-15,000
Closed -$562K
XNCR icon
69
Xencor
XNCR
$2.15B
– –
-18,000
Closed -$395K
FPRX
70
DELISTED
Five Prime Therapeutics, Inc.
FPRX
– –
-115,500
Closed -$2.53M
DERM
71
DELISTED
Dermira, Inc.
DERM
– –
-108,000
Closed -$3M
AKAO
72
DELISTED
Achaogen Inc
AKAO
– –
-204,538
Closed -$2.2M
JUNO
73
DELISTED
Juno Therapeutics, Inc.
JUNO
– –
-50,000
Closed -$2.28M
ENTL
74
DELISTED
Entellus Medical, Inc. Common Stock
ENTL
– –
-341,468
Closed -$8.32M
1 2
3

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q1 2018 Portfolio in Review

As of Q1 2018, International Biotechnology Trust held 75 positions worth $256M, down 9.6% from $284M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

International Biotechnology Trust withdrew a net $13M in Q1 2018, closing 12 positions and reducing 12 holdings. Its most notable exit was Nektar Therapeutics, an estimated $12.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

Against the trend, International Biotechnology Trust opened a new position in Jazz Pharmaceuticals worth $2.87M.

  • International Biotechnology Trust's largest Q1 2018 buy was Jazz Pharmaceuticals: 19,000 shares worth $2.87M.
  • International Biotechnology Trust added most to Neurocrine Biosciences in Q1 2018, an estimated $9.88M increase.
  • International Biotechnology Trust's biggest Q1 2018 reduction was Acadia Pharmaceuticals, cutting an estimated $8.06M.
  • International Biotechnology Trust fully exited Nektar Therapeutics in Q1 2018, selling an estimated $12.6M.
  • International Biotechnology Trust's ten largest holdings make up 49% of its $256M portfolio in Q1 2018.
  • International Biotechnology Trust opened 10 new positions and closed 12 in Q1 2018.
  • International Biotechnology Trust's portfolio value fell 9.6% quarter-over-quarter to $256M.

Based on International Biotechnology Trust's 13F filing for Q1 2018, filed 15 May 2018.